Sophia Abene

NYC officials confirm 113 cases and six deaths in Central Harlem cooling tower–linked outbreak; separate Bronx investigation underway after cases tied to hot water system.

Allergist and immunologist Juanita Mora, MD, urges vaccination, masking, and outreach to safeguard vulnerable communities.

9-month pilot study showed a 55% reduction in resident colonization with MRSA, VRE, and ESBL, but contamination of high-touch surfaces persisted in rooms of MDRO carriers.

Systematic review finds FMT and standardized microbiome products outperform antibiotics in efficacy and safety.

Regulators cite four new serious adverse event reports, halting US distribution while global access efforts continue.

This week, people with HIV are living longer on antiretroviral therapy but face elevated comorbidity risks, requiring tailored screening and multidisciplinary care as they age, and more.

New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.

STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.

A decade-long study finds the ratio independently predicts risk, with patients aged ≥30 facing higher progression rates.

First-in-class IL-15 agonist aims to address persistent post-COVID symptoms by enhancing immune clearance and restoring T cell memory.

ECDC warns climate shifts are driving longer mosquito seasons and expanding disease transmission, calling for stronger surveillance, vector control, and clinician preparedness.

Philippa Easterbrook, MD, MPH, FRCP, explains barriers in primary care, the promise of community models, and how simplified guidelines could expand access to treatment.

Morris County resident was infected despite no recent travel; risk to public remains low, officials say.

Julia Moore Vogel, PhD, says the LoCITT study aims to expand access through a fully remote design using CareEvolution’s MyDataHelps platform.

The renewed federal panel aims to improve vaccine oversight and restore public trust amid declining immunization rates and ongoing concerns about vaccine ingredients.

This week, predictive microbiome models for C difficile, synergistic antibiotic strategies for E faecalis, to pharmacy-led hepatitis C care, and more.

The FDA announces two voluntary recalls so far in August 2025 for Camembert and Brie cheeses sold in multiple states and NYC.

As virus season begins, Leilani Valdes, MD, MBA, FCAP, highlights the lab’s role in early detection and the importance of informed, respectful dialogue on vaccines.

Robert Bransfield, MD, discusses how microbes may influence violent behavior and global instability through biological and environmental pathways.

Ty Stoner of Walgreens Specialty Pharmacy on navigating barriers, building partnerships, and improving access for vulnerable populations.

Pathologist Leilani Valdes, MD, MBA, FCAP, explains the role of PCR testing, early surveillance, and vaccine education in protecting community health.

A new study finds that personalized gut microbiome models may predict C difficile colonization risk and guide targeted probiotic treatment.

Sharon Nachman, MD, breaks down the latest on Stratus and Nimbus variants and what families should consider as schools resume.

Vir initiates phase 2b head-to-head trial of novel combination therapy vs bulevirtide.

Pediatric infectious disease expert Sharon Nachman, MD, explains how to identify symptoms, assess travel risk, and prevent mosquito-borne illness in kids.

This week, from synthetic biosecurity concerns to gaps in maternal hepatitis C screening, rising COVID cases, antimicrobial resistance, fast-tracked CF therapies, and more.

After a three-month review, the FDA and EMA have cleared continued use of IXCHIQ in adults 60+, adding new safety warnings for elderly individuals with chronic conditions.

Cost-effectiveness of COVID-19 vaccination in older adults amid rising US cases and limited booster access.

Despite updated guidelines for universal hepatitis C virus screening in pregnancy, testing rates remain well below targets, missing chances to prevent perinatal transmission.

Low vaccine uptake, immunity gaps, and new antiviral data raise alarms ahead of a potential late-summer surge.